### Supplementary Table 2. Baseline characteristics of the study population stratified by non-NAFLD (defined by HSI), liver steatosis, and advanced liver fibrosis

| Characteristic            | NAFLD (−) (n=1,696) | Hepatic steatosis alone (n=1,413) | Advanced liver fibrosis (n=79) | P value |
|---------------------------|----------------------|-----------------------------------|-------------------------------|---------|
| Age, yr                   | 57.7±10.0            | 55.0±10.0                         | 65.7±6.6ab                    | 0.003c |
| Male sex                  | 785 (46.3)           | 754 (53.4)a                       | 52 (65.8)ab                   | <0.001c |
| Duration of diabetes, yr  | 8.1±7.2              | 6.4±6.2a                          | 8.1±6.6b                      | <0.001c |
| BMI, kg/m²                | 22.7±2.2             | 26.3±2.7a                         | 29.1±2.8ab                    | <0.001c |
| WC, cm                    | 79.8±7.5             | 87.8±7.5a                         | 92.3±6.9ab                    | <0.001c |
| SBP, mm Hg                | 132.6±17.8           | 136.6±17.4                        | 142.2±16.6ab                  | <0.001c |
| DBP, mm Hg                | 84.1±10.9            | 94.6±279.6a                       | 86.3±11.2                     | 0.179   |
| FPG, mg/dL                | 158.1±59.2           | 162.6±56.9a                       | 151.0±56.7                    | 0.186   |
| HbA1c, %                  | 8.3±2.1              | 8.4±1.8a                          | 8.0±1.4c                      | 0.970   |
| KITT, %/min               | 2.2±1.0              | 1.9±0.9a                          | 1.7±0.7c                      | <0.001c |
| Total cholesterol, mg/dL  | 192.3±39.1           | 200.4±41.6a                       | 193.3±36.3                    | <0.001c |
| Triglyceride, mg/dL       | 127.4±80.3           | 170.6±137.3a                      | 147.6±62.1ab                  | <0.001c |
| HDL-C, mg/dL              | 53.2±14.4            | 49.1±12.5a                        | 49.3±12.1b                    | <0.001c |
| LDL-C, mg/dL              | 113.8±34.0           | 118.9±36.9a                       | 114.8±31.6                    | 0.011c  |
| AST, IU/L                 | 26.9±13.4            | 29.2±17.5a                        | 32.2±15.8b                    | <0.001c |
| ALT, IU/L                 | 23.4±13.8            | 38.6±33.0a                        | 29.7±14.9b                    | <0.001c |
| eGFR, mL/min/1.73 m²      | 91.0±15.5            | 91.9±15.5                         | 85.6±14.8ab                   | 0.986   |
| Hs-CRP, mg/dL             | 0.6 (0.3–1.3)        | 0.9 (0.5–1.9)a                    | 1.0 (0.5–2.1)a                | <0.001c |
| Hypertension              | 421 (24.8)           | 438 (31.0)a                       | 26 (32.9)                     | <0.001c |
| Insulin                   | 192 (11.3)           | 143 (10.1)                        | 13 (16.5)                     | 0.157   |
| Metformin                 | 668 (39.4)           | 689 (48.8)a                       | 25 (31.6)b                    | <0.001c |
| Sulfonylurea              | 878 (51.8)           | 742 (52.5)                        | 45 (57.0)                     | 0.638   |
| Thiazolidinedione         | 167 (9.8)            | 114 (8.1)                         | 14 (17.7)b                    | 0.007c  |
| ARB/ACE inhibitors        | 76 (4.5)             | 91 (6.4)a                         | 9 (11.4)a                     | 0.004c  |
| Statin                    | 234 (13.8)           | 267 (18.9)a                       | 4 (5.1)b                      | <0.001c |
| Incident CKD              | 255 (15.0)           | 198 (14.0)                        | 26 (32.9)ab                   | <0.001c |

Values are presented as mean±standard deviation, number (%), or median (interquartile range). NAFLD, nonalcoholic fatty liver disease; HSI, hepatic steatosis index; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; KITT, rate constant for plasma glucose disappearance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; Hs-CRP, high-sensitivity C-reactive protein; ARB, angiotensin II receptor blockers; ACE, angiotensin converting enzyme; CKD, chronic kidney disease.

Indicates $P<0.05$ compared with NAFLD (−). Indicates $P<0.05$ compared with hepatic steatosis without advanced liver fibrosis, Statistically significant.